357 related articles for article (PubMed ID: 25890191)
1. Oncolytic activity of reovirus in HPV positive and negative head and neck squamous cell carcinoma.
Cooper T; Biron VL; Fast D; Tam R; Carey T; Shmulevitz M; Seikaly H
J Otolaryngol Head Neck Surg; 2015 Feb; 44(1):8. PubMed ID: 25890191
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of Human Papillomavirus-Associated Head and Neck Cancers in a Veteran Population.
Shay SG; Chang E; Lewis MS; Wang MB
JAMA Otolaryngol Head Neck Surg; 2015 Sep; 141(9):790-6. PubMed ID: 26270931
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity of cervical carcinoma cells to vesicular stomatitis virus-induced oncolysis: potential role of human papilloma virus infection.
Le Boeuf F; Niknejad N; Wang J; Auer R; Weberpals JI; Bell JC; Dimitroulakos J
Int J Cancer; 2012 Aug; 131(3):E204-15. PubMed ID: 22173567
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapeutic alteration of VEGF-/PDGF- and PDGF-Rα/β expression by imatinib in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
Schultz JD; Mühlheim K; Erben P; Hofheinz RD; Faber A; Thorn C; Sommer JU; Hörmann K; Sauter A
Oncol Rep; 2011 Nov; 26(5):1099-109. PubMed ID: 21805039
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus in metastatic lymph nodes from unknown primary head and neck squamous cell carcinoma.
Compton AM; Moore-Medlin T; Herman-Ferdinandez L; Clark C; Caldito GC; Wang XI; Thomas J; Abreo FW; Nathan CO
Otolaryngol Head Neck Surg; 2011 Jul; 145(1):51-7. PubMed ID: 21493313
[TBL] [Abstract][Full Text] [Related]
6. Increased radiosensitivity of HPV-positive head and neck cancer cell lines due to cell cycle dysregulation and induction of apoptosis.
Arenz A; Ziemann F; Mayer C; Wittig A; Dreffke K; Preising S; Wagner S; Klussmann JP; Engenhart-Cabillic R; Wittekindt C
Strahlenther Onkol; 2014 Sep; 190(9):839-46. PubMed ID: 24715240
[TBL] [Abstract][Full Text] [Related]
7. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.
Fakhry C; Westra WH; Li S; Cmelak A; Ridge JA; Pinto H; Forastiere A; Gillison ML
J Natl Cancer Inst; 2008 Feb; 100(4):261-9. PubMed ID: 18270337
[TBL] [Abstract][Full Text] [Related]
8. Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer.
Spanos WC; Nowicki P; Lee DW; Hoover A; Hostager B; Gupta A; Anderson ME; Lee JH
Arch Otolaryngol Head Neck Surg; 2009 Nov; 135(11):1137-46. PubMed ID: 19917928
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic effects of the oncolytic herpes simplex virus HSV1716 alone and in combination with cisplatin in head and neck squamous cell carcinoma.
Mace AT; Harrow SJ; Ganly I; Brown SM
Acta Otolaryngol; 2007 Aug; 127(8):880-7. PubMed ID: 17763002
[TBL] [Abstract][Full Text] [Related]
10. In vitro investigation of head and neck cancer stem cell proportions and their changes following X-ray irradiation as a function of HPV status.
Reid P; Wilson P; Li Y; Marcu LG; Staudacher AH; Brown MP; Bezak E
PLoS One; 2017; 12(10):e0186186. PubMed ID: 29028842
[TBL] [Abstract][Full Text] [Related]
11. Imatinib-associated matrix metalloproteinase suppression in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.
Umbreit C; Aderhold C; Faber A; Sauter A; Hofheinz RD; Stern-Straeter J; Hoermann K; Schultz JD
Oncol Rep; 2014 Aug; 32(2):668-76. PubMed ID: 24890748
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic adenoviruses targeted to Human Papilloma Virus-positive head and neck squamous cell carcinomas.
LaRocca CJ; Han J; Salzwedel AO; Davydova J; Herzberg MC; Gopalakrishnan R; Yamamoto M
Oral Oncol; 2016 May; 56():25-31. PubMed ID: 27086483
[TBL] [Abstract][Full Text] [Related]
13. Detection of human papillomavirus-related squamous cell carcinoma cytologically and by in situ hybridization in fine-needle aspiration biopsies of cervical metastasis: a tool for identifying the site of an occult head and neck primary.
Zhang MQ; El-Mofty SK; Dávila RM
Cancer; 2008 Apr; 114(2):118-23. PubMed ID: 18300234
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapeutic alteration of VEGF, PDGF and PDGFRα/β expression under 5-FU vs. docetaxel in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
Aderhold C; Umbreit C; Faber A; Sauter A; Sommer JU; Birk R; Erben P; Hofheinz RD; Stern-Straeter J; Hörmann K; Schultz JD
Anticancer Res; 2013 May; 33(5):1951-61. PubMed ID: 23645743
[TBL] [Abstract][Full Text] [Related]
15. Multimodal approach using oncolytic adenovirus, cetuximab, chemotherapy and radiotherapy in HNSCC low passage tumour cell cultures.
Dias JD; Guse K; Nokisalmi P; Eriksson M; Chen DT; Diaconu I; Tenhunen M; Liikanen I; Grénman R; Savontaus M; Pesonen S; Cerullo V; Hemminki A
Eur J Cancer; 2010 Feb; 46(3):625-35. PubMed ID: 20006487
[TBL] [Abstract][Full Text] [Related]
16. Unexpected alteration of β-catenin and c-KIT expression by 5-FU and docetaxel in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.
Umbreit C; Aderhold C; Faber A; Sommer JU; Sauter A; Hofheinz RD; Stern-Sträter J; Hoermann K; Schultz JD
Anticancer Res; 2013 Jun; 33(6):2457-65. PubMed ID: 23749896
[TBL] [Abstract][Full Text] [Related]
17. Integration of high-risk human papillomavirus into cellular cancer-related genes in head and neck cancer cell lines.
Walline HM; Goudsmit CM; McHugh JB; Tang AL; Owen JH; Teh BT; McKean E; Glover TW; Graham MP; Prince ME; Chepeha DB; Chinn SB; Ferris RL; Gollin SM; Hoffmann TK; Bier H; Brakenhoff R; Bradford CR; Carey TE;
Head Neck; 2017 May; 39(5):840-852. PubMed ID: 28236344
[TBL] [Abstract][Full Text] [Related]
18. Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC.
Aderhold C; Faber A; Umbreit C; Birk R; Weiss C; Sommer JU; Hörmann K; Schultz JD
Anticancer Res; 2015 Apr; 35(4):1951-9. PubMed ID: 25862847
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapeutic alteration of β-catenin and c-kit expression by imatinib in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.
Schultz JD; Sommer JU; Hoedt S; Erben P; Hofheinz RD; Faber A; Thorn C; Hörmann K; Sauter A
Oncol Rep; 2012 Jan; 27(1):270-80. PubMed ID: 21993766
[TBL] [Abstract][Full Text] [Related]
20. Treatment response of HPV-positive and HPV-negative head and neck squamous cell carcinoma cell lines.
Nagel R; Martens-de Kemp SR; Buijze M; Jacobs G; Braakhuis BJ; Brakenhoff RH
Oral Oncol; 2013 Jun; 49(6):560-6. PubMed ID: 23578372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
